| scholarly article | Q13442814 |
| P356 | DOI | 10.1158/0008-5472.CAN-05-2372 |
| P698 | PubMed publication ID | 16204062 |
| P2093 | author name string | Christine M Lohse | |
| Alan P Fields | |||
| Capella Weems | |||
| Lee Jamieson | |||
| Eric S Edell | |||
| Andras Khoor | |||
| Roderick P Regala | |||
| P433 | issue | 19 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | lung cancer | Q47912 |
| P304 | page(s) | 8905-8911 | |
| P577 | publication date | 2005-10-01 | |
| P1433 | published in | Cancer Research | Q326097 |
| P1476 | title | Atypical protein kinase C iota is an oncogene in human non-small cell lung cancer | |
| P478 | volume | 65 |
| Q39708962 | "Atypical" regulation of Hedgehog-dependent cancers |
| Q37688222 | 14-3-3ζ and aPKC-ι synergistically facilitate epithelial-mesenchymal transition of cholangiocarcinoma via GSK-3β/Snail signaling pathway |
| Q58173395 | A Cancer-Associated Mutation in Atypical Protein Kinase C Occurs in a Substrate-Specific Recruitment Motif |
| Q40063308 | A novel quinoline, MT477: suppresses cell signaling through Ras molecular pathway, inhibits PKC activity, and demonstrates in vivo anti-tumor activity against human carcinoma cell lines |
| Q38882024 | A small molecule inhibitor of atypical protein kinase C signaling inhibits pancreatic cancer cell transformed growth and invasion |
| Q39560142 | AP1B plays an important role in intestinal tumorigenesis with the truncating mutation of an APC gene |
| Q37103690 | Actin cytoskeletal mediators of motility and invasion amplified and overexpressed in head and neck cancer |
| Q33332140 | Activation of p38MAPK contributes to expanded polyglutamine-induced cytotoxicity. |
| Q40054747 | Amplification of PRKCI, located in 3q26, is associated with lymph node metastasis in esophageal squamous cell carcinoma |
| Q24294931 | Amplitude control of protein kinase C by RINCK, a novel E3 ubiquitin ligase |
| Q38185497 | Apico-basal polarity complex and cancer |
| Q38038637 | Apicobasal polarity and cell proliferation during development |
| Q28249478 | Asymmetric and symmetric stem-cell divisions in development and cancer |
| Q28292920 | Asymmetric cell division of stem and progenitor cells during homeostasis and cancer |
| Q39843379 | Atypical protein kinase C activity is required for extracellular matrix degradation and invasion by Src-transformed cells |
| Q27305890 | Atypical protein kinase C induces cell transformation by disrupting Hippo/Yap signaling |
| Q37143104 | Atypical protein kinase C iota expression and aurothiomalate sensitivity in human lung cancer cells |
| Q39224377 | Atypical protein kinase C phosphorylates Par6 and facilitates transforming growth factor β-induced epithelial-to-mesenchymal transition |
| Q37373237 | Atypical protein kinase C{iota} is required for bronchioalveolar stem cell expansion and lung tumorigenesis |
| Q38162656 | Atypical protein kinase Cι as a human oncogene and therapeutic target |
| Q57271956 | Aurothiomalate Inhibits Transformed Growth by Targeting the PB1 Domain of Protein Kinase Cι |
| Q41868891 | Cancer stem cell, niche and EGFR decide tumor development and treatment response: A bio-computational simulation study |
| Q35037676 | Cancer-associated protein kinase C mutations reveal kinase's role as tumor suppressor |
| Q36925556 | Cell polarity in development and cancer. |
| Q37204597 | Cell polarity in morphogenesis and metastasis |
| Q37435101 | Chapter 3: acquisition of membrane polarity in epithelial tube formation patterns, signaling pathways, molecular mechanisms, and disease. |
| Q54593106 | Coexpression of aPKCλ/ι and IL-6 in prostate cancer tissue correlates with biochemical recurrence. |
| Q42754969 | Colorectal laterally spreading tumors show characteristic expression of cell polarity factors, including atypical protein kinase C λ/ι, E-cadherin, β-catenin and basement membrane component |
| Q30577989 | Control of MT1-MMP transport by atypical PKC during breast-cancer progression |
| Q37333588 | Control of tumourigenesis by the Scribble/Dlg/Lgl polarity module |
| Q30496644 | Coordination of glioblastoma cell motility by PKCι |
| Q38390024 | Copy number gains of FGFR1 and 3q chromosome in squamous cell carcinoma of the lung |
| Q42438368 | Dap160/intersectin binds and activates aPKC to regulate cell polarity and cell cycle progression |
| Q42434834 | Disruption of precise regulation of αPKC expression and cellular localization is associated with cervical cancer progression |
| Q37191526 | Divide and conquer: how asymmetric division shapes cell fate in the hematopoietic system |
| Q24316134 | Ect2 links the PKCiota-Par6alpha complex to Rac1 activation and cellular transformation |
| Q90216826 | Effects of Atypical Protein Kinase C Inhibitor (DNDA) on Lung Cancer Proliferation and Migration by PKC-ι/FAK Ubiquitination Through the Cbl-b Pathway |
| Q40236633 | Effects on ligand interaction and membrane translocation of the positively charged arginine residues situated along the C1 domain binding cleft in the atypical protein kinase C isoforms |
| Q37968480 | Epithelial cell polarity, stem cells and cancer |
| Q38038639 | Epithelial cell polarity: what flies can teach us about cancer. |
| Q101574540 | Equivocal, explicit and emergent actions of PKC isoforms in cancer |
| Q28296029 | Evi1 is a survival factor which conveys resistance to both TGFbeta- and taxol-mediated cell death via PI3K/AKT |
| Q35323930 | Expression of polarity genes in human cancer |
| Q35835275 | FBXO31 promotes cell proliferation, metastasis and invasion in lung cancer. |
| Q92490693 | Fragment-based Discovery of a Small-Molecule Protein Kinase C-iota Inhibitor Binding Post-kinase Domain Residues |
| Q33836807 | Genetic variability of the mTOR pathway and prostate cancer risk in the European Prospective Investigation on Cancer (EPIC). |
| Q28475905 | Genome-wide profile of pleural mesothelioma versus parietal and visceral pleura: the emerging gene portrait of the mesothelioma phenotype |
| Q43877393 | High expression of KIBRA in low atypical protein kinase C-expressing gastric cancer correlates with lymphatic invasion and poor prognosis |
| Q50700668 | High expression of partitioning defective 3-like protein is associated with malignancy in colorectal cancer. |
| Q34828123 | Identification of a small molecule with synthetic lethality for K-ras and protein kinase C iota |
| Q39202768 | Inhibition of atypical protein kinase Cι induces apoptosis through autophagic degradation of β-catenin in esophageal cancer cells |
| Q58696958 | Inhibition of atypical protein kinase C‑ι effectively reduces the malignancy of prostate cancer cells by downregulating the NF-κB signaling cascade |
| Q37254004 | Integrative genomics analysis identifies candidate drivers at 3q26-29 amplicon in squamous cell carcinoma of the lung |
| Q37121568 | Interruption of RNA processing machinery by a small compound, 1-[(4-chlorophenyl)methyl]-1H-indole-3-carboxaldehyde (oncrasin-1). |
| Q40974176 | Lack of an association between the aPKCλ/ι expression in prostate cancer and the patient outcomes. |
| Q37333631 | Linking epithelial polarity and carcinogenesis by multitasking Helicobacter pylori virulence factor CagA. |
| Q30370835 | Loss of Par3 promotes breast cancer metastasis by compromising cell-cell cohesion. |
| Q42478228 | Loss of cell polarity protein Lgl2 in foveolar-type gastric dysplasia: correlation with expression of the apical marker aPKC-zeta |
| Q40184230 | Loss of function of the candidate tumor suppressor prox1 by RNA mutation in human cancer cells |
| Q30416351 | Loss of the Par3 polarity protein promotes breast tumorigenesis and metastasis |
| Q37361313 | Matrix metalloproteinase-10 is a critical effector of protein kinase Ciota-Par6alpha-mediated lung cancer |
| Q34251083 | Matrix metalloproteinase-10 is required for lung cancer stem cell maintenance, tumor initiation and metastatic potential |
| Q34056327 | Matrix metalloproteinase-10 promotes Kras-mediated bronchio-alveolar stem cell expansion and lung cancer formation |
| Q35678516 | Meta-analysis of oncogenic protein kinase Ciota signaling in lung adenocarcinoma |
| Q57460102 | Modulation of the Hippo pathway and organ growth by RNA processing proteins |
| Q28081405 | Molecular pathways: novel approaches for improved therapeutic targeting of Hedgehog signaling in cancer stem cells |
| Q37588487 | Of the atypical PKCs, Par-4 and p62: recent understandings of the biology and pathology of a PB1-dominated complex |
| Q38077454 | PKC signaling in glioblastoma. |
| Q39826662 | PKC-delta binds to E-cadherin and mediates EGF-induced cell scattering |
| Q24297584 | PKC-ι promotes glioblastoma cell survival by phosphorylating and inhibiting BAD through a phosphatidylinositol 3-kinase pathway |
| Q36780352 | PKCι counteracts oxidative stress by regulating Hsc70 in an esophageal cancer cell line |
| Q38981503 | PKCι depletion initiates mitotic slippage-induced senescence in glioblastoma |
| Q37466903 | PKCι maintains a tumor-initiating cell phenotype that is required for ovarian tumorigenesis. |
| Q37520978 | PKCι regulates nuclear YAP1 localization and ovarian cancer tumorigenesis |
| Q34038395 | PKCλ/ι signaling promotes triple-negative breast cancer growth and metastasis |
| Q47154650 | PRKCI promotes immune suppression in ovarian cancer |
| Q37333585 | Par complex in cancer: a regulator of normal cell polarity joins the dark side |
| Q42065297 | Par6 is phosphorylated by aPKC to facilitate EMT. |
| Q40216411 | Par6-aPKC uncouples ErbB2 induced disruption of polarized epithelial organization from proliferation control |
| Q37608855 | Phase I dose escalation study of the PKCι inhibitor aurothiomalate for advanced non-small-cell lung cancer, ovarian cancer, and pancreatic cancer. |
| Q34760619 | Phosphoproteomic analysis of signaling pathways in head and neck squamous cell carcinoma patient samples |
| Q37679354 | Polarity protein alterations in carcinoma: a focus on emerging roles for polarity regulators |
| Q36828937 | Polarity proteins as regulators of cell junction complexes: implications for breast cancer |
| Q37333610 | Polarity proteins in migration and invasion |
| Q36881687 | Polarity regulators and the control of epithelial architecture, cell migration, and tumorigenesis. |
| Q59072618 | Protein Kinase C (PKC) Isozymes and Cancer |
| Q28115044 | Protein Kinase Cι Drives a NOTCH3-dependent Stem-like Phenotype in Mutant KRAS Lung Adenocarcinoma |
| Q38171231 | Protein kinase C and cancer: what we know and what we do not. |
| Q37208253 | Protein kinase C betaII and PKCiota/lambda: collaborating partners in colon cancer promotion and progression |
| Q35987724 | Protein kinase C iota as a therapeutic target in alveolar rhabdomyosarcoma. |
| Q24652905 | Protein kinase C iota: human oncogene, prognostic marker and therapeutic target |
| Q36980701 | Protein kinase C isozymes as therapeutic targets for treatment of human cancers |
| Q34981351 | Protein kinase C zeta regulates human pancreatic cancer cell transformed growth and invasion through a STAT3-dependent mechanism |
| Q35733900 | Protein kinase C δ is a downstream effector of oncogenic K-ras in lung tumors |
| Q39736038 | Protein kinase Ciota is required for pancreatic cancer cell transformed growth and tumorigenesis |
| Q37491175 | Protein kinase Cα suppresses Kras-mediated lung tumor formation through activation of a p38 MAPK-TGFβ signaling axis. |
| Q34787801 | Protein kinase Cι expression and oncogenic signaling mechanisms in cancer. |
| Q53722723 | Protein kinase Cι is a new prognostic factor in gastric cancer. |
| Q64916137 | Protein kinase Cι: A versatile oncogene in the lung. |
| Q54314273 | Quantification of PKC family genes in sporadic breast cancer by qRT-PCR: evidence that PKCι/λ overexpression is an independent prognostic factor. |
| Q39453904 | Regulation of Cdk7 activity through a phosphatidylinositol (3)-kinase/PKC-ι-mediated signaling cascade in glioblastoma |
| Q34739540 | Regulation of glioblastoma cell invasion by PKC iota and RhoB. |
| Q37537542 | Regulation of polarized morphogenesis by protein kinase C iota in oncogenic epithelial spheroids. |
| Q39436597 | Repression of cancer cell senescence by PKCι. |
| Q38196268 | Rewiring cell polarity signaling in cancer |
| Q37956397 | Role of genotyping in non-small cell lung cancer treatment: current status |
| Q34165690 | Role of symmetric and asymmetric division of stem cells in developing drug resistance. |
| Q90320971 | Sirt1 protects from K-Ras-driven lung carcinogenesis |
| Q37388961 | Spatiotemporal dynamics of phosphorylation in lipid second messenger signaling |
| Q33915077 | TNF is a key cytokine mediating neutrophil cytotoxic activity in breast cancer patients |
| Q48678789 | Targeting atypical protein kinase C iota reduces viability in glioblastoma stem-like cells via a notch signaling mechanism |
| Q37673912 | Targeting oncogenic protein kinase Cι for treatment of mutant KRAS LADC. |
| Q90612036 | Targeting the tyrosine kinase inhibitor-resistant mutant EGFR pathway in lung cancer without targeting EGFR? |
| Q24337113 | The PRKCI and SOX2 oncogenes are coamplified and cooperate to activate Hedgehog signaling in lung squamous cell carcinoma |
| Q36301305 | The Par complex and integrins direct asymmetric cell division in adult intestinal stem cells |
| Q35973562 | The Proto-oncogene PKCι regulates the alternative splicing of Bcl-x pre-mRNA. |
| Q28258198 | The RNA binding protein FXR1 is a new driver in the 3q26-29 amplicon and predicts poor prognosis in human cancers |
| Q37387817 | The Rac-GAP Bcr is a novel regulator of the Par complex that controls cell polarity. |
| Q36510237 | The chromosome 3q26 OncCassette: A multigenic driver of human cancer |
| Q37333603 | The epithelial polarity program: machineries involved and their hijacking by cancer. |
| Q37120960 | The evolution of our understanding on glioma |
| Q33827549 | The guanine nucleotide exchange factor (GEF) Ect2 is an oncogene in human cancer |
| Q38981224 | The interruption of PKC-ι signaling and TRAIL combination therapy against glioblastoma cells |
| Q36965068 | The prognostic impact of NF-kappaB p105, vimentin, E-cadherin and Par6 expression in epithelial and stromal compartment in non-small-cell lung cancer |
| Q40106069 | The protein kinase C inhibitor, H7, inhibits tumor cell invasion and metastasis in mouse melanoma via suppression of ERK1/2. |
| Q60920983 | The signaling axis atypical protein kinase C λ/ι-Satb2 mediates leukemic transformation of B-cell progenitors |
| Q38268431 | Tuning the signalling output of protein kinase C. |
| Q42378305 | Two novel atypical PKC inhibitors; ACPD and DNDA effectively mitigate cell proliferation and epithelial to mesenchymal transition of metastatic melanoma while inducing apoptosis. |
| Q39025641 | Utility and applications of orthotopic models of human non-small cell lung cancer (NSCLC) for the evaluation of novel and emerging cancer therapeutics |
| Q36168226 | Wealth of opportunity - the C1 domain as a target for drug development |
| Q60044508 | aPKC controls endothelial growth by modulating c-Myc via FoxO1 DNA-binding ability |
| Q37364129 | aPKClambda/iota promotes growth of prostate cancer cells in an autocrine manner through transcriptional activation of interleukin-6. |
| Q33279290 | aPKCzeta cortical loading is associated with Lgl cytoplasmic release and tumor growth in Drosophila and human epithelia |
| Q47805359 | miR-217-5p induces apoptosis by directly targeting PRKCI, BAG3, ITGAV and MAPK1 in colorectal cancer cells |
| Q42965204 | miR-219 inhibits the growth and metastasis of TSCC cells by targeting PRKCI. |
Search more.